• Quoin Pharmaceuticals announced acceptance of a peer-reviewed paper on QRX003 for Netherton syndrome in Dermatology and Therapy.
• Results were already presented in the manuscript, including a pediatric compassionate-use case report describing fully healed skin and elimination of itch.
• Prior updates cited improving outcomes across enrolled pediatric compassionate-use patients, with no treatment-related adverse events reported.
• Interim Phase 2/3 trial results disclosed in August showed most early participants improved on the study’s main clinical assessment.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Quoin Pharmaceuticals Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610060630PRIMZONEFULLFEED9840001) on October 06, 2026, and is solely responsible for the information contained therein.